NASDAQ:CALC

CalciMedica Q2 2026 Earnings Results & Report

CalciMedica logo
$1.17 -0.05 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica beat analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.45 versus the -$1.4250 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

CalciMedica EPS Results

Actual EPS
-$0.45
Consensus EPS
-$1.4250
Beat/Miss
Beat by +$0.9750
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Q2 2026 Earnings FAQ

CalciMedica (NASDAQ:CALC) reported earnings of -$0.45 per share for Q2 2026, beating the consensus estimate of -$1.4250. The report was announced on Tuesday, August 11, 2026.

CalciMedica Earnings Headlines

FY2026 EPS Estimates for CalciMedica Raised by HC Wainwright
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
CalciMedica (CALC) Set to Release Earnings on Wednesday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation.

The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.

View CalciMedica Profile